Empire Genomics Licenses Biomarker from Emory University for Multiple Myeloma CDx | GenomeWeb

NEW YORK (GenomeWeb News) – Empire Genomics said today that it has acquired the exclusive license to a genomic biomarker from Emory University for the development of a molecular diagnostic test for determining which therapies may be most suitable for specific patients with multiple myeloma.

A phase II biomarker-driven clinical trial is being conducted using the technology to validate its ability to predict outcomes of new generations of drugs for the blood cell cancer, Empire Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.